Pesquisa

Artigos no Europe PMC

Resumo do Europe PMC lido nesta página. Não é bula, diagnóstico nem orientação clínica. O PDF completo protegido por direitos não entra no BETARUBI.

• Europe PMC · 2026

  Factors associated with smoking cessation among adolescents: A retrospective study in a smoking cessation outpatient clinic.

  Aksu SB, Öztürk GZ, Taş BG.

  Introduction This study aimed to evaluate smoking cessation status and factors associated with cessation among individuals aged ≤20 years who attended a smoking cessation outpatient clinic during the first month of follow-up. Methods This was a single-center, descriptive study conducted among adolescents who applied to a Smoking Cessation Outpatient Clinic. Patients' sociodemographic characteristics and smoking histories were recorded, and nicotine dependence was assessed using the Fagerström test for nicotine dependence (FTND). Statistical analyses included descriptive statistics, group comparisons using appropriate parametric or nonparametric tests, and multivariable logistic regression. Results A total of 229 adolescents were included. At one month, the overall cessation rate was 7.9% (n=18). At one month, adolescents who quit smoking had lower daily cigarette consumption and lower nicotine dependence scores. In multivariable analysis, only the FTND score remained independently associated with cessation (AOR=0.807; 95% CI: 0.660-0.987). Conclusions Among Turkish adolescents seeking smoking cessation support, lower nicotine dependence was the primary predictor of short-term quitting success. For public health policies, early identification and timely intervention in adolescent smoking are essential to reduce the potential long-term health risks and future healthcare costs, particularly given the increasingly early age of smoking initiation.

• Europe PMC · 2026

  The Ethical Role of Dermatologists in Smoking Cessation Counseling.

  Zieneldien T, Kizy SM, Coberly E, Ma S, Aljassabi A, Grant-Kels JM.

  Smoking has been associated with increased disease severity, poorer treatment response, and adverse outcomes in several dermatologic conditions, including hidradenitis suppurativa (HS), psoriasis, cutaneous lupus erythematosus, and chronic wounds. Although smoking cessation counseling is traditionally viewed as the responsibility of primary care clinicians, dermatologists frequently encounter patients whose skin disease may be influenced by tobacco use. This raises an important ethical question: when does counseling regarding lifestyle behaviors fall within the scope of dermatologic practice? Herein, we discuss the ethical justification for dermatologists to engage in smoking cessation counseling through the principles of beneficence, autonomy, and justice. Beneficence supports counseling when tobacco use is relevant to disease severity, treatment response, procedural outcomes, or prevention. At the same time, counseling must respect patient autonomy and avoid approaches that may contribute to emotional distress, perceived judgment, or damage to the therapeutic alliance. Justice further requires recognition of the social and structural barriers that can make smoking cessation difficult for many patients. More broadly, smoking serves as a model for addressing other modifiable health behaviors that may affect skin health, including obesity, alcohol use, and vaccination status. Dermatologists are not obligated to comprehensively manage all lifestyle factors; however, they have an ethical/professional responsibility to discuss behaviors that have meaningful implications for patient outcomes.

• Europe PMC · 2026

  Letter regarding "preoperative smoking cessation in suprainguinal bypasses".

  Jummala S, Kumari C M, Tripathi S, Sati DM.

  A fonte não publicou resumo para este artigo. O BETARUBI não abre o texto noutro site.

• Europe PMC · 2026

  Tobacco Smoking Cessation and Cancer Stage.

  Matsuo K, Lee MW, Friedman EL, Erfani H, Luhar RD, O'Bryan JV, Ouzounian AJ, Yao JA, Roman LD.

  A fonte não publicou resumo para este artigo. O BETARUBI não abre o texto noutro site.

• Europe PMC · 2026

  Interventions for smoking cessation in inpatient psychiatry settings.

  Plever S, Kisely SR, Bonevski B, Siskind D, Yamazaki-Tan J, Thaker P, Vos G, Kim D, Guillaumier A, Gartner CE.

  Rationale Tobacco smoking is a leading preventable cause of premature morbidity and mortality in people living with severe mental illness. Smoking rates are disproportionately high and abstinence rates low in people with severe mental illness, despite their reported interest in quitting being comparable to that of the general population. Inpatient psychiatry settings have been identified as opportune places to promote and support tobacco cessation amongst people with severe mental illness who smoke, particularly since many hospitals have implemented smoke-free policies. Evidence is needed to guide policy and practice for tobacco cessation interventions within inpatient psychiatry settings. Objectives To assess the effects of smoking cessation interventions on tobacco smoking in adults receiving inpatient psychiatry treatment. Search methods We searched the following bibliographical databases and clinical trial registers from inception until 10 February 2026: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase (Elsevier), PubMed, PsycINFO (EBSCOhost), CINAHL Complete (EBSCOhost), ProQuest Dissertations and Theses Global, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). We also handsearched the annual meeting abstracts for the Society for Research on Nicotine and Tobacco (SRNT) and screened reference lists of eligible studies. Eligibility criteria We included randomised controlled trials (RCTs) and cluster-RCTs that assessed interventions for tobacco cessation amongst people of 18 years and older who were inpatients in psychiatry settings. Interventions had to be initiated in the psychiatry inpatient setting and aimed at supporting smoking cessation. Outcomes Our critical outcome was smoking abstinence at six months (biochemically verified) and our important outcomes included serious adverse events. Risk of bias We used the Cochrane risk of bias tool (RoB 2) to assess the outcomes of our review. Synthesis methods We synthesised results using meta-analysis where appropriate, calculating risk ratios using the inverse-variance random-effects model. Where this was not possible, we synthesised results following Synthesis Without Meta-analysis (SWiM) guidelines. We used GRADE to assess our level of certainty in the evidence for our two key outcomes. Included studies We included 10 studies that involved 2262 people in total. Three trials were conducted in the USA, two in Australia, two in Taiwan, two in Iran, and one in Israel. The studies took place in emergency or acute and long-stay psychiatric settings. In most studies, the participants had a mix of diagnoses (e.g. mood disorders, anxiety disorders, schizophrenia), and three studies involved only participants with schizophrenia or schizophrenia-type disorders. Five studies tested smoking cessation counselling plus nicotine replacement therapy with post-discharge follow-up support versus usual care; one study tested a group behavioural programme for smoking reduction versus waitlist control; and four studies tested pharmacotherapy interventions including smoking medications (bupropion versus placebo, cytisine versus nicotine replacement therapy) and nicotine replacement therapy (different types and doses). Synthesis of results We found low-certainty evidence of increased smoking abstinence from interventions that provided counselling with nicotine replacement therapy and post-discharge support, compared to usual care, when measured six months after the start of the intervention or hospital discharge (RR 1.81, 95% CI 1.33 to 2.47; P 2 = 0%; 5 studies, 1611 participants; low-certainty evidence). Across studies, serious adverse events (SAEs) were low. We pooled four studies reporting deaths at 6 to 18 months after the start of the intervention or hospital discharge. We found that the intervention of smoking cessation counselling plus nicotine replacement therapy with post-discharge support may result in a s

• Europe PMC · 2026

  Clearing the Smoke on Smoking Cessation.

  Udelsman BV, Kim AW.

  A fonte não publicou resumo para este artigo. O BETARUBI não abre o texto noutro site.

• Europe PMC · 2026

  Smoking Cessation Support in General Practice: Perspectives of Australian General Practitioners

  Salehin M, Lam L, Rahman MA.

  General practitioners (GPs) are central to smoking cessation; however, their own smoking may influence cessation-related perceptions and practices. This study examined Australian GPs’ perceptions of smoking cessation support, implementation of the 5As model, and associations with their smoking status. A cross-sectional online survey of Australian GPs used a questionnaire primarily based on the Global Health Professional Survey, with items adapted from a previous Australian study. Uni-variate and multivariable logistic regression analyses examined associations between perceptions, 5As implementation, smoking status, and sociodemographic charac-teristics. Among 178 participants, 57% were male, 92% were migrants, and 7.3% were daily smokers. Compared with never smokers, current smokers were more likely to agree that GPs who smoke are less likely to advise patients to quit (AOR=4.02, 95% CI:1.20–13.45), and less likely to view GPs as role models (AOR=0.13, 95% CI:0.03–0.48) or believe GP advice promotes quitting (AOR=0.11, 95% CI:0.01–0.88). Current smokers were less familiar with the 5As than ex-smokers (AOR=0.12, 95% CI:0.02–0.65). Four-fifths reported no cessation-counselling training. Barriers were patient resistance, limited consultation time, and lack of reimbursement. GPs’ smoking status was associated with cessation-related perceptions and practices. Targeted training and system-level support may strengthen smoking cessation care in Australian primary care.

• Europe PMC · 2026

  Smoking Cessation Intervention for People With Tuberculosis.

  Liu Z, Peng L, Jiang M.

  A fonte não publicou resumo para este artigo. O BETARUBI não abre o texto noutro site.